| アブストラクト | OBJECTIVES: The objectives of this study were to retrospectively investigate the patient characteristics, treatment patterns, healthcare resource utilization (HCRU), and healthcare costs related to management of neurofibromatosis type 1 (NF1) in Japan. METHODS: Cohorts of NF1 patients with or without plexiform neurofibromas (PN) were identified from the Medical Data Vision database in 2008-2019. Baseline characteristics, NF1 medications, HCRU, and associated costs were assessed using descriptive statistics. All-cause HCRU and costs following the first confirmed NF1 diagnosis date were analyzed per patient per year (PPPY) in Japanese Yen (JPY) and United States Dollar (USD). RESULTS: A total of 4394 NF1 patients without PN and 370 NF1 patients with PN were identified. The mean age was 35.0 and 36.9 years, respectively. The proportion of patients with PN treated with medications was higher than that in patients without PN (except for antirheumatic/immunologic agents). Analgesics/non-steroidal anti-inflammatory drugs were the most frequently prescribed NF1 medications (44.3% and 56.0% in patients without and with PN, respectively), followed by inpatient prescriptions of opioids/opioid-like agents (17.8% and 27.6%, respectively). Inpatient admissions accounted for the highest costs in both cohorts with the average cost PPPY being JPY 2,133,277 (USD 19,861) for patients without PN and JPY 1,052,868 (USD 9802) for patients with PN. CONCLUSIONS: NF1 is treated primarily with supportive care with analgesics/non-steroidal anti-inflammatory drugs being the most frequently prescribed NF1 medications in Japan. Findings underscored the unmet need and substantial economic burden among patients with NF1 and highlighted the need for new treatment options for patients with this disease. |
|---|
| ジャーナル名 | Current medical research and opinion |
|---|
| Pubmed追加日 | 2024/2/26 |
|---|
| 投稿者 | Yoshida, Yuichi; Tozawa, Keiichi; Koto, Ryo; Iwao, Chikako; Kim, YongJin; Ban, Lu; Barut, Volkan |
|---|
| 組織名 | Division of Dermatology, Department of Medicine of Sensory and Motor Organs,;Faculty of Medicine, Tottori University, Yonago, Japan.;AstraZeneca K.K, Osaka, Japan.;Evidera, Saint-Laurent, Canada.;Evidera, PPD, Beijing, China.;AstraZeneca, Cambridge, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38404173/ |
|---|
